Literature DB >> 10379219

Treatment advances in rheumatoid arthritis.

E R Arriola1, N P Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10379219      PMCID： PMC1305584     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  10 in total

Review 1.  New insights in the pathogenesis of rheumatoid arthritis.

Authors:  F C Breedveld
Journal:  J Rheumatol Suppl       Date:  1998-07

2.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

3.  The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.

Authors:  J P Davis; G A Cain; W J Pitts; R L Magolda; R A Copeland
Journal:  Biochemistry       Date:  1996-01-30       Impact factor: 3.162

4.  Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.

Authors:  T Pincus; L F Callahan; W G Sale; A L Brooks; L E Payne; W K Vaughn
Journal:  Arthritis Rheum       Date:  1984-08

5.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

Authors:  K Seibert; Y Zhang; K Leahy; S Hauser; J Masferrer; W Perkins; L Lee; P Isakson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

6.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.

Authors:  J A Mitchell; P Akarasereenont; C Thiemermann; R J Flower; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

7.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

8.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

9.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09

10.  Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.

Authors:  L S Simon; F L Lanza; P E Lipsky; R C Hubbard; S Talwalker; B D Schwartz; P C Isakson; G S Geis
Journal:  Arthritis Rheum       Date:  1998-09
  10 in total
  1 in total

Review 1.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.